Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MRG003 in recurrent or metastatic nasopharyngeal carcinoma
CTR20210995Phase 2Active
- Sponsor
- Hangzhou Miracogen
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in nasopharyngeal carcinoma (NPC), sponsored by Hangzhou Miracogen. Started Aug 2021; status: active.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20210995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210995.